# PBS Biotech

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/pbs-biotech

- Industry: Biotechnology
- Headquarters: Camarillo, US
- Website: www.pbsbiotech.com
- Total disclosed funding: $35M
- Latest round: Series E (Dec 16, 2022)
- Investors on record: 2

## About

Based in the US, PBS Biotech, Inc. specializes in the manufacturing of innovative bioreactors that support the development of cell therapies for critical health challenges.Founded in 2006 and headquartered in Camarillo, California, PBS Biotech, Inc. focuses on the production of scalable bioreactor systems. The company has completed three investment deals, with the most recent occurring on September 11, 2024. In this round, PBS Biotech raised USD 8.5 mn in growth capital from investors including BroadOak Capital Partners and Avego Healthcare Capital. The company's CEO is Brian Lee.PBS Biotech specializes in the manufacturing of scalable, single-use bioreactors, ranging from 0.1L to 80L in capacity. The core offerings include a diverse line of bioreactors designed to facilitate the development of cell therapy products aimed at addressing critical health challenges such as cancer, diabetes, and heart failure. These bioreactors empower scientists and researchers by enabling optimized cell growth and production, supporting applications in allogeneic therapies derived from cells like induced pluripotent stem cells, mesenchymal stem cells, and CAR-T or NK cells. PBS Biotech serves a global clientele that includes academic institutions, research organizations, and biotechnology firms focused on cell and gene therapy. The company has positioned its products in markets across North America, Europe, and Asia, ensuring a broad reach to entities engaged in therapeutic developments.PBS Biotech generates revenue through direct sales of its bioreactor systems and related products, which are tailored to meet the specific needs of its clients. The sales structure predominantly follows a B2B model, where customers, including pharmaceutical companies and research institutions, request custom quotes for various bioreactor capacities, such as the PBS-0.1, PBS-0.5, PBS-3, PBS-15, and PBS-80 models. Transactions typically involve one-time purchases or ongoing supply agreements depending on the scale of the client's operations. The company also offers accessory products and services, which may include application support for optimizing cell yield and quality, crucial for facilitating the commercialization of therapeutic products and enhancing efficiency in cell manufacturing processes.In September 2024, PBS Biotech, Inc. secured approximately USD 8.5 mn in growth capital funding to accelerate new product innovation, process development services, and quality system improvements to support the cell therapy industry. The company plans to design and launch new bioreactor models aimed at expanding its product offerings. Additionally, PBS Biotech is targeting expansion into new geographic markets, particularly in Europe and Asia, to broaden its reach by 2025.

## Funding rounds

- Series E, Dec 16, 2022, $35M — BroadOak Capital Partners, Avego

## Investors

- BroadOak Capital Partners (https://capitalatlas.ai/funds/broadoak-capital-partners) — Series E
- Avego (https://capitalatlas.ai/funds/avego) — Series E